HekeTiss
Please fill in all fields below to contact HekeTiss.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | CHF100k | Debt | |
| Total Funding | 000k | ||
HekeTiss SA, a spin-off from the University of Geneva and University Hospitals of Geneva, is dedicated to developing advanced therapies for patients suffering from chronic ulcers. These ulcers, often resulting from conditions like diabetes and cardiovascular diseases, impact over 1% of the global population, causing significant pain and reduced quality of life. HekeTiss's flagship product, TrophiPatch, is a cell-based skin patch designed to improve wound healing through the regenerative capabilities of adipose-derived stem cells. The company is poised to begin human trials in 2023, following successful preclinical animal testing. HekeTiss operates in the healthcare sector, targeting patients with chronic skin conditions. Its business model focuses on research and development, with revenue potential from licensing and partnerships in the medical field. The company is led by experts in dermatology and biotechnology, including Dr. Costantino Brembilla and Nicolo', who have extensive experience in skin regeneration research.
Keywords: stem cells, skin regeneration, chronic ulcers, TrophiPatch, adipose tissue, cicatrization, healthcare, biotechnology, dermatology, research.